Follow
Patient benefit
Patient benefit is used to assess the efficacy and feasibility of medical treatments. To assess patient benefit, a clear understanding of the patient's health prior to and after a procedure, treatment, or intervention is compared. Treatments which generate a patient benefit, with minimal or acceptable risks, may be approved for further clinical use.
SEP 23, 2021 | 11:00 AM
Date: September 23, 2021 Time: 11:00am (PST), 2:00pm (EST) Learning Objectives: Provide an overview of the renin-angiotensin-aldosterone system (RAAS) and implication on Hypertension Describ...
AUG 25, 2021 | 12:00 AM
Parkinson’s disease (PD) is the second most common neurodegenerative disorder with multiple motor and non-motor symptoms. PD is characterized by the presence on proteinaceous neuronal...
JUL 29, 2021 | 9:00 AM
Date: July 29, 2021 Time: 1:00am (PDT), 4:00am (EDT) Traditionally limited to a small number of phenotypes and mutations suggested to specific risk groups, the emerging field of genomics i...
JUL 15, 2021 | 10:00 AM
Date: July 15, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Sigma Metrics plays a critical role in laboratory medicine. Abbott is committed to helping your laboratory achieve excellence in clinica...
JUL 08, 2021 | 8:00 AM
Date: July 8, 2021 Time: 8:00am (PDT) Cell-based chimeric antigen receptor (CAR) T cell therapies have rapidly advanced in recent years, with a variety of targets in clinical research and se...
JUN 02, 2021 | 3:00 PM
PD-L1 is a key inhibitor of T cell activation that is often over-expressed in cancer to escape immune surveillance and promote tumor progression. Blocking antibodies against PD-L1 or its rec...
JUN 02, 2021 | 12:00 AM
Learning Objectives: 1. Define “universal CARs” and describe their mechanism of action. 2. Explain current challenges in CAR T cell therapy. 3. Describe potential benefits and ch...
JUN 02, 2021 | 12:00 AM
Immune checkpoint therapy (ICT) is a front-line treatment for lung cancer; however, low mutational burden and ‘non-T cell inflamed’ signatures predict poor responses to ICT in ~5...
MAY 13, 2021 | 9:00 AM
Date: May 13, 2021 Time: 9:00am PDT The value proposition for laboratory medicine has long been theorized, estimated and debated. Despite decades of effort and intangible proof, the strategi...
APR 29, 2021 | 12:05 PM
New genomic technologies are changing the face of cancer care, as well as accelerating our biological understanding of cancer. Cris will summarise several parallel cancer initiatives in New...
APR 29, 2021 | 4:35 PM
Next Generation Sequencing (NGS) based molecular tests have been the one of the major focus for the expansion of molecular service provided by Haemato-oncology Diagnostic Service (HODS) in R...
